Education
About Us
Working with TipRanks
Follow Us
Biocryst Pharmaceuticals (BCRX)
NASDAQ:BCRX
Earnings Data
Report Date
Apr 30, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.05Last Year’s EPS
0Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum, record profitability, solid balance sheet and financing, successful pediatric approval, and highly encouraging clinical data for Navenibart and BCX17725. Management emphasized disciplined capital allocation, profitability, and scalable commercialization. Near-term headwinds include a seasonal Q1 reauthorization impact, rising 2026 R&D spend to support late-stage activities, uncertainty in pediatric uptake timing, and exposure of Navenibart regulatory timing to enrollment and data milestones. Overall, the positives — strong growth, record non-GAAP operating profit (+198% YoY), robust clinical efficacy (Navenibart mean attack reductions ~90%+, median 97%), and solid liquidity — outweigh the manageable near-term challenges.Company Guidance
Record ORLADEYO Full-Year Revenue
Full-year ORLADEYO revenue of $601.8M, up 38% year-over-year and up 43% when excluding the European business sold in October 2025.
Strong Overall Revenue and Profitability
Non-GAAP total revenue increased 45% year-over-year in 2025; non-GAAP ORLADEYO revenues rose by approximately $169M (about 43% YoY). Non-GAAP operating profit jumped to $214M, a 198% increase YoY and the highest in company history.
Robust Balance Sheet and Financing Optionality
Ended 2025 with $337.5M in cash and investments and secured a $400M financing facility with Blackstone Life Sciences to support growth and optionality.
Pediatric Approval for ORLADEYO Pellets
FDA approved ORLADEYO pellets for children aged 2 to <12 in December 2025; pediatric launch included in 2026 guidance (expected to be a small contribution in 2026 but with substantial long-term upside).
Navenibart Clinical Efficacy and Development Progress
Phase II ALPHA-SOLAR data showed mean attack rate reductions of 92% (every 3 months) and 90% (every 6 months); mean attack rate decreased from 2.23/month to 0.16/month (fewer than two attacks per year). Median attack rate reduction was 97%. Pivotal Phase III enrollment (145 patients) is recruiting well and expected to complete around mid-2026.
Clear Regulatory & Development Timeline for Navenibart
Company plans a BLA submission by end of 2027 (driven by the need for 12 months of safety data) with a pathway to approval by late 2028, assuming trial timelines are met.
BCX17725 Early-Stage Results and Patient Study Initiation
Healthy volunteer Phase I (single/multiple ascending doses) completed with BCX17725 safe and well-tolerated; observed epidermal distribution and linear exposure; half-life ~12–19 days. Patient cohorts (Part 4 up to 12 patients) prioritized to generate data by year-end 2026.
Commercial Execution and Patient Persistence
Real-world persistence strong: pivotal trial showed just over 50% of starters stayed on ORLADEYO for 2 years with a 91% reduction from baseline; real-world 60% persistence at 12 months and nearly 50% of U.S. patients who tried ORLADEYO over the past 5 years remain on therapy. Sales & marketing generated ~4x return on ORLADEYO net sales.
Conservative, Disciplined Financial Guidance
2026 ORLADEYO revenue guidance of $625M–$645M (midpoint ≈13% growth vs. 2025 adjusted for Europe); 2026 non-GAAP OpEx guidance $450M–$470M that includes Astria expenses, with management emphasizing R&D discipline and focus on capital allocation.
BCRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BCRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $7.55 | $7.90 | +4.64% |
Nov 03, 2025 | $7.32 | $6.86 | -6.28% |
Aug 04, 2025 | $7.95 | $8.73 | +9.81% |
May 05, 2025 | $8.93 | $11.03 | +23.52% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Biocryst Pharmaceuticals (BCRX) report earnings?
Biocryst Pharmaceuticals (BCRX) is schdueled to report earning on Apr 30, 2026, TBA (Confirmed).
What is Biocryst Pharmaceuticals (BCRX) earnings time?
Biocryst Pharmaceuticals (BCRX) earnings time is at Apr 30, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BCRX EPS forecast?
BCRX EPS forecast for the fiscal quarter 2026 (Q1) is 0.05.
